How does TICER work?
TICER is based on a simple decision framework, comparing no biomarker testing to biomarker testing, as illustrated in Figure a. If testing is performed, the biomarker prevalence α determines the proportion of patients for which a specific therapy is added or spared. Each endpoint is a clinical state corresponding to the patient’s progression free survival, overall survival, as well as associated costs and HRQOL.
Figure b displays the Cost (top) and HRQOL profile (bottom) for a general scenario. We consider treatment time t for targeted therapy, t(Targeted), for standard therapy, t(Standard), post-treatment stable disease (from t to PFS), and disease progression (PFS to OS) for both treatment arms. For simplicity, we assume that costs of quality of life of stable and progressed disease are equivalent between treatment arms.